In the past week, PFE stock has gone down by -0.02%, with a monthly decline of -5.52% and a quarterly plunge of -19.05%. The volatility ratio for the week is 2.71%, and the volatility levels for the last 30 days are 2.49% for Pfizer Inc. The simple moving average for the past 20 days is -2.60% for PFE’s stock, with a -20.07% simple moving average for the past 200 days.

Is It Worth Investing in Pfizer Inc. (NYSE: PFE) Right Now?

Pfizer Inc. (NYSE: PFE) has a higher price-to-earnings ratio of 16.30x compared to its average ratio, , and the 36-month beta value for PFE is at 0.59. Analysts have varying views on the stock, with 11 analysts rating it as a “buy,” 1 rating it as “overweight,” 14 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price suggested by analysts for PFE is $39.71, which is $10.03 above the current market price. The public float for PFE is 5.64B, and currently, shorts hold a 0.84% of that float. The average trading volume for PFE on November 16, 2023 was 28.23M shares.

PFE) stock’s latest price update

The stock price of Pfizer Inc. (NYSE: PFE) has plunged by -1.71 when compared to previous closing price of 30.19, but the company has seen a -0.02% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-16 that Though Pfizer’s (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.

Analysts’ Opinion of PFE

Many brokerage firms have already submitted their reports for PFE stocks, with UBS repeating the rating for PFE by listing it as a “Neutral.” The predicted price for PFE in the upcoming period, according to UBS is $34 based on the research report published on October 20, 2023 of the current year 2023.

PFE Trading at -7.70% from the 50-Day Moving Average

After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.98% of loss for the given period.

Volatility was left at 2.49%, however, over the last 30 days, the volatility rate increased by 2.71%, as shares sank -4.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.29% lower at present.

During the last 5 trading sessions, PFE rose by +0.15%, which changed the moving average for the period of 200-days by -32.40% in comparison to the 20-day moving average, which settled at $30.39. In addition, Pfizer Inc. saw -42.09% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PFE starting from Gottlieb Scott, who purchase 1,000 shares at the price of $38.58 back on May 08. After this action, Gottlieb Scott now owns 6,000 shares of Pfizer Inc., valued at $38,580 using the latest closing price.

Gottlieb Scott, the Director of Pfizer Inc., purchase 1,000 shares at $38.42 during a trade that took place back on May 05, which means that Gottlieb Scott is holding 5,000 shares at $38,425 based on the most recent closing price.

Stock Fundamentals for PFE

Current profitability levels for the company are sitting at:

The net margin for Pfizer Inc. stands at +31.26. The total capital return value is set at 29.59, while invested capital returns managed to touch 25.39. Equity return is now at value 11.05, with 5.10 for asset returns.

Based on Pfizer Inc. (PFE), the company’s capital structure generated 40.82 points at debt to equity in total, while total debt to capital is 28.99. Total debt to assets is 19.80, with long-term debt to equity ratio resting at 37.09. Finally, the long-term debt to capital ratio is 26.34.

When we switch over and look at the enterprise to sales, we see a ratio of 2.65, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 8.95 and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.22.


In conclusion, Pfizer Inc. (PFE) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.